Hematopoietic growth factors in cancer patients with invasive fungal infections

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 1, 1997, Pages 56-63

  Offner, F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANTIFUNGAL ACTIVITY; CANCER PATIENT; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HUMAN; INFECTION PREVENTION; MORBIDITY; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL;

GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; NEOPLASMS;

EID: 0031045801     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01575122     Document Type: Conference Paper

References (55)

1. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S, Naoe S, Okudaira M, Scevola D, van't Wout J: Fungal infections in cancer patients: an international autopsy survey. Clinical Infectious Diseases 1994, 18: 525-532.
2. Walsh TJ, Hiemenz J, Pizzo PA: Evolving risk factors for invasive fungal infections: all neutropenic patients are not the same. Clinical Infectious Diseases 1994, 18: 793-798.
3. Schwartz RS, Mackintosh FR, Schrier SL, Greenberg PL: Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 1984, 53: 411-419.
4. Bodey GP, Buckley M, Sathe YS: Quantitative relationship between circulating leukocytes and infection in patients with leukemia. Annals of Internal Medicine 1966, 64: 328-340.
5. Maksymiuk AN, Thongprasert S, Hopfer R, Luna M, Fainstein V, Bodey GP: Systemic candidiasis in cancer patients. American Journal of Medicine 1984, 77, Supplement 4D: 20-27.
6. Lieschke J, Burgess AW: Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor (parts I and II). New England Journal of Medicine 1992, 327: 28-35, 99-106.
7. Harmenberg J, Höglund M, Hellström-Lindberg E: G and GM-CSF in oncology and oncological haematology. European Journal of Haematology 1994, 52: 1-28.
8. Lord BI, Gurney H, Chang J, Thatcher N, Growther D, Dexter TM: Haematopoietic cell kinetics in humans treated with rGM-CSF. International Journal of Cancer 1992, 50: 26-31.
9. Lord BI, Bronchud MM, Owens S: The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proceedings of the National Academy of Sciences of the USA 1989, 86: 9499-9503.
10. Gabrilove JL, Jakubowski A, Fain K: Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. Journal of Clinical Investigation 1988, 82: 1454-1461.
11. Duhrsen U, Villeval JL, Boyd J, Kamourakis G, Morstyn G, Metcalf D: Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988, 72: 2074-2081.
12. Steward WP, Scarffe JY, Austin R: Recombinant human granulocyte macrophage colony stimulating factor (rh GM-CSF) given as daily short infusions - a phase I dose-toxicity study. British Journal of Cancer 1989, 59: 142-145.
13. Fleischmann J, Golde DW, Weisbart RH, Gasson JC: Granulocyte macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 1986, 68: 708-711.
14. Roilides E, Walsh TJ, Pizzo PA, Rubin M: Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. Journal of Infectious Diseases 1991, 163: 579-583.
15. Yuo A, Kitagawa S, Ohsaka A: Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes: potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi-receptor expression and adherence. Blood 1989, 74: 2144-2149.
16. Griffin JD, Spertini O, Ernst TJ: Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecular-1 on human neutrophils, monocytes and their precursors. Journal of Immunology 1990, 145: 576-584.
17. Spertini O, Kansas GS, Munro JM, Griffin JD, Tedder TF: Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin. Nature 1991, 349: 961-964.
18. Myrvang Høgåsen AK, Abrahamsen TG: Increased C3 production in human monocytes after stimulation with Candida albicans is suppressed by granulocyte-macrophage colony-stimulating factor. Infection and Immunity 1993, 61: 1779-1785.
19. Nathan CF: Respiratory burst in adherent human neutrophils: triggering by colony-stimulating factors CSF-GM and CSF-G. Blood 1989, 73: 301-306.
20. Ohsaka A, Kitagawa S, Sakamoto S: In vivo activation of human neutrophil functions by administration of recombinant granulocyte colony-stimulating factor in patients with malignant lymphoma. Blood 1989, 74: 2743-2748.
21. Fabian I, Baldwin GC, Golde DN: Biosynthetic granulocyte-macrophage colony-stimulating factor enhances neutrophil cytotoxicity towards human leukemia cells. Leukemia 1987, 1: 613-617.
22. Fukunaga R, Ishizaka-Ikeda E, Nagata S: Growth and differentiation signals mediated by different regions in the cytoplasmic domain of granulocyte colony-stimulating factor receptor. Cell 1993, 74: 1079-1087.
23. Arnaout MA, Wang EA, Clark SC, Sieff CA: Human granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. Journal of Clinical Investigation 1986, 78: 597-601.
24. Peters WP, Stuart A, Affronti ML, Kim CS, Coleman RE: Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. Blood 1988, 72: 1310-1315.
25. Addison IE, Johnson B, Devereux S, Goldstone AN, Linch DC: Granulocyte-macrophage colony-stimulating factor may inhibit neutrophil migration in vivo. Clinical Experimental Immunology 1989, 76: 149-153.
26. Heidenreich S, Gong JH, Schmidt A, Nain M, Gemsa D: Macrophage activation by granulocyte-macrophage colony-stimulating factor. Priming for enhanced release of tumor necrosis factor alpha and prostaglandin E2. Journal of Immunology 1989, 143: 1198-1205.
27. Polak WA: Protective effect of human granulocyte colony stimulating factor (hG-CSF) on Candida infections in normal and immunosuppressed mice. Mycoses 1992, 34: 109-118.
28. Lechner AJ, Lamprech KE, Potthoff LH, Tredway TL, Matuschak GM: Recombinant GM-CSF reduces lung injury and mortality during neutropenic Candida sepsis. American Journal of Physiology 1994, 266: 561-568.
29. Nelson S: Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the non-neutropenic host: an overview. Clinical Infectious Diseases 1994, 18, Supplement 2: 197-204.
30. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara J, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishan W, Yahanda A, Vincent M, Stewart M, Glaspy J: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. New England Journal of Medicine 1991, 325: 164-170.
31. Trillet-Lenoir V, Green J, Manegold C, Van Pawel J, Gatzemeier V, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, Ewen C: Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer 1993, 29A: 319-324.
32. Pettengell R, Gurney H, Radford JA, Deakin DP, Wilkinson PM, Kane K, Bentley J, Crowther D: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma. A randomized controlled trial. Blood 1992, 80: 1430-1434.
33. Gisselbrecht C, Coiffier B, Lepage E: Placebo-controlled phase III trial of lenograstim in aggressive non-Hodgkin's lymphoma. Annals of Oncology 1994, 91: 454.
34. Gerhartz JJ, Engehard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G, Mueller R Huhn D, Musch R, Siegert W, Gerhartz D, Hartlapp JH, Thiel E, Huber C, Peschl C, Spann W, Emmerich B, Schadek C, Westerhausen M, Pees HW, Radtke H, Engert A, Terhardt E, Schick H, Binder T, Fuchs R, Hasford J, Brandmaier R, Stern AC, Jones TC, Eherlich HJ, Stein H, Parwaresch M, Tiemann M, Lennert K: Randomized double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993, 82: 2329-2339.
35. Nichols C, Bajorin D, Schmoll HJ: VIP chemotherapy with/without GM-CSF for poor risk, relapsed or refractory germ cell tumors. Proceedings of the American Society for Clinical Oncology 1991, 10: 167.
36. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA (for the Cancer and Leukemia Group B): Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New England Journal of Medicine 1995, 332: 1671-1677.
37. Dombret H, Chastang C, Fenaux P, Reiffers J. Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L (for the AML Cooperative Study Group): A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New England Journal of Medicine 1995, 332: 1678-1682.
38. Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, McKendrick J. Toner G, Bradstock K, Lieschke M, Cruickshank S, Tomita DK, Hoffman EW, Fox RM, Morstyn G: Filgrastim in patients with chemotherapy-induced febrile neutropenia. Annals of Internal Medicine 1994, 121: 492-501.
39. Biesma G, deVries EG, Willemse PHB, Sluiter WJ, Postmus PE, Limburg PC, Stern AC, Vellenga E: Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer 1990, 26: 932-936.
40. Riikonen P, Saarinen V, Mäkipernaa A, Hovi L, Kamulainen A, Pihkala J, Jalanko H: Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal 1994, 13: 197-202.
41. Mayordomo JI, Rivera F, Diaz-Purente MT, Lianes P, Cortes-Funes H: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. Journal of the National Cancer Institute 1993, 85: 1251-1252.
42. Nemunaitis J, Rabinowe SN, Singer JW, Buchner CD, Appelbaum F: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New England Journal of Medicine 1991, 324: 1773-1778.
43. Link H, Boogaerts MA, Carella AM: A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high dose chemotherapy and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992, 80: 2188-2195.
44. Stahel RA, Jost LM, Cerny TH, Pichert G, Honegger H, Tobber A, Jacky E, Fey M, Platzer E: Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone-marrow transplantation for high-risk lymphoid malignancies. Journal of Clinical Oncology 1994, 12: 1931-1939.
45. Masaoka T, Takaku F, Kato S: Recombinant human granulocyte colony stimulating factor in allogeneic bone marrow transplantation. Experimental Hematology 1989, 1047-1050.
46. Anasetti C, Anderson G, Appelbaum FR, Buchner CD, Martin PH, Nemunaitis J, Singer J, Storb R, Sullivan KM, Thomas ED, Hansen JA: Phase III study of rh GM-CSF in allogeneic marrow transplantation from unrelated donors. Blood 1993, 82, Supplement 1: 454.
47. de Witte T, Gratwohl A, Van der Lely N: Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil T-cell-depleted bone marrow transplantation. Blood 1992, 79: 1359-1365.
48. Ozer H: Hematopoietic colony-stimulating factors. Clinical practice guidelines. Proceedings of the American Society of Clinical Oncology 1995, Educational Symposia: 221-231.
49. Lyman GH, Lyman CG, Sanderson RA, Balducci L: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. Journal of the National Cancer Institute 1993, 85: 488-493.
50. Offner F, Schoch G, Fisher L, Martin P: Mortality hazard as related to the duration of neutropenia after marrow transplantation. Blood 1994, 84, Supplement 1: 487.
51. Mempel K, Pietsch T, Menzel T, Zeidler C, Weite K: Increased serum levels of granulocyte colony-stimulating factor in patients with severe congenital neutropenia. Blood 1991, 77: 1919-1922.
52. Kawakami M, Tsutsumi H, Kumakawa T, Abe H, Hirai M, Kurosawa S, Mori M, Fukushima M: Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990, 76: 1962-1964.
53. Cebon J, Layton JE, Maher D, Morstyn G: Endogenous haemopoietic growth factors in neutropenia and infection. British Journal of Haematology 1994, 86: 265-274.
54. Morstyn G, Campbell L, Souza LM: Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988, i: 667-672.
55. Bodey GP, Anaissie E, Guttermans J, Vadhan-Raj S: Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. European Journal of Clinical Microbiology & Infectious Diseases 1994, 13, Supplement 2: 18-22.